Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination

Abstract

We report a novel use for low-dose RT, not as a direct antitumor modality but as an immunomodulator capable of driving and expanding antitumor immunity against metastatic tumor sites following ISV.